A Us Single Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New clinical analyses and real-world data continue to demonstrate the benefit of treatment with CAMZYOS (mavacamten) for patients with symptomatic obstructive HCM 

United statesRoland chenPfizer allianceYork heart associationBristol myers squibbA us single centerHead of developmentCardiovascular healthAmerican heart associationScientific sessionsNew york heart associationBristol myers squibb pfizer allianceSenior vice presidentWorld adherenceMore drugsNew pharmacologic insights